Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-62 (cancelled).

- 63. (Previously presented) A method of inhibiting mast cell degranulation in a subject, the method comprising administering to the subject a pharmaceutically effective amount of a therapeutic agent, wherein said therapeutic agent comprises a complex molecule which comprises a first segment having an amino acid sequence AAVALLPAVLLALLAP (SEQ ID NO: 3) linked via a linker to a second segment having an amino acid sequence KNNLKECGLY (SEQ ID NO:1), thereby inhibiting mast cell degranulation in the subject.
- 64. (Previously presented) The method of claim 63, wherein said complex molecule is a peptide having an amino acid sequence AAVALLPAVLLALLAPKNNLKECGLY (SEQ ID NO:7) and comprises a cyclization between lysine at position 17 and the C terminus of the peptide.
- 65. (Previously presented) The method of claim 63, wherein said complex molecule is a peptide having an amino acid sequence AAVALLPAVLLALLAPKNNLKECGLY (SEQ ID NO:7) and comprises a succinyl residue at the N terminus of the peptide.
- 66. (Previously presented) The method of claim 63, wherein the mast cell degranulation is associated with a condition selected from the group consisting of nasal allergy, an allergic reaction in an eye of the subject, an allergic reactions in the skin of the subject, acute urticaria, psoriasis, psychogenic or allergic asthma, interstitial cystitis, bowel diseases, migraines, and multiple sclerosis.

Appl. No. 10/009,809 Amdt. dated June 28, 2007

Reply to Final Office Action of March 1, 2007

- (Previously presented) The method of claim 63, wherein the step of administration of said therapeutic agent is performed by topical administration.
- (Previously presented) The method of claim 67, wherein said topical administration is to the eye, the skin or to a mucous membrane of the subject.
- 69. (Previously presented) The method of claim 63, wherein administration of said therapeutic agent is performed by inhalation or by intranasal administration.
- 70. (Previously presented) The method of claim 63, wherein administration of said therapeutic agent is performed by oral or systemic parenteral administration.
 - 71. (Canceled).
- (Previously presented) The method of claim 63, wherein said linker is a covalent bond.
- 73. (Previously presented) The method of claim 72, wherein said covalent bond is a peptide bond.
- 74. (Previously presented) A method of inhibiting mast cell degranulation in a subject, the method comprising administering to the subject a pharmaceutically effective amount of a therapeutic agent, wherein said therapeutic agent comprises a complex molecule which comprises a peptide having a first segment having an amino acid sequence

 AAVALLPAVLLALLAP (SEQ ID NO:3) and a second segment having an amino acid sequence KENLKDCGLF (SEQ ID NO:2) or KNNLKECGLY (SEQ ID NO:1), said first segment being joined to said second segment through a linker, thereby inhibiting mast cell degranulation in the subject.

Appl. No. 10/009,809 Amdt. dated June 28, 2007 Reply to Final Office Action of March 1, 2007

- 75. (Previously presented) The method of claim 74, wherein said mast cell degranulation is IgE-dependent.
- 76. (Previously presented) The method of claim 74, wherein said mast cell degranulation is IgE-independent.
- 77. (Previously presented) The method of claim 63, wherein said mast cell degranulation is IgE-dependent.
- 78. (Previously presented) The method of claim 63, wherein said mast cell degranulation is IgE-independent.
- (Previously presented) The method of claim 63, wherein said mast cell degranulation is IgE-dependent.
 - 80. (Canceled).